Adam's practice is focused on international arbitration, as well as dispute resolution generally. He represents and advises clients in a broad range of sectors, most significantly in construction and engineering and commercial/corporate disputes, as well as those in the pharmaceutical sector.
He has conducted arbitrations under the rules of most major arbitral institutions and under various governing laws, with a specific emphasis on English and Singapore law. Adam also has advised clients in enforcement/challenge proceedings in respect of arbitration awards in national courts.
Adam currently is based in Geneva, on secondment from Singapore, where he worked for several years. During this time, Adam gained considerable experience in disputes throughout Asia, both in arbitration and court proceedings. Prior to this, Adam was based in the Firm's London office.
Examples of Adam's recent experience include:
Representing a multinational corporation in a S$500 million ICC arbitration, seated in Singapore and governed by Singapore law, involving claims for the rescission of an SPA for the acquisition of a landmark asset.
Representing the US and Indonesian subsidiaries of a global engineering group in three parallel SIAC arbitrations, governed by English and Indonesian law, arising out of the construction of installations at a coal mine in South Kalimantan, Indonesia.
Representing a European EPC contractor in a US$150 million ICC arbitration, seated in London and governed by English law, in respect of a chemical processing plant in Western Australia.
Representing a European contractor in an ad-hoc UNCITRAL arbitration, seated in New Delhi, relating to the construction of two petrochemical plants in India.
Representing a global marine engineering company in a US$150 million ICC arbitration, seated in Singapore and governed by Singapore law, arising from a dispute over a joint venture.
Representing a European oil company in an application to the English High Court to have an arbitration award set-aside under the UK Arbitration Act 1996.
Representing a US pharmaceutical company in a US$200 million ICC arbitration, seated in Geneva and governed by New York, in relation to a licence and development agreement with a European counterpart.
Advising a Swiss pharmaceutical company in respect of a potential arbitration under a licence agreement with a US supplier.
Representing a European inspection and certification company in an ICC arbitration, seated in Paris and governed by Swiss law, in respect of services provided in the African mining sector.